Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia (US)

Login to access report north_east
Contact sales account_box

Non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) encompass a heterogeneous group of hematological malignancies broadly classified into indolent and aggressive subtypes. Treatment approaches vary by subtype, but rituximab in combination with chemotherapy remains the mainstay of treatment across NHL subtypes. Recent label expansions are giving hematologist-oncologists an ever-increasing array of treatment options, including Epkinly (Genmab / AbbVie) and Brukinsa (BeiGene) for relapsed/refractory (R/R) follicular lymphoma (FL) and Breyanzi (Bristol Myers Squibb) for R/R CLL, R/R FL, and R/R mantle-cell lymphoma (MCL). These advances, alongside shifting prescribing patterns and increasing competition, are reshaping the treatment of NHL and CLL.

Questions answered

  • What are the uptake and patient share of key therapies and regimens across all NHL / CLL subtypes, according to surveyed hematologist-oncologists?
  • How does physician prescribing of current treatments vary based on genetic mutations and CAR T-cell- and transplant-eligibility criteria?
  • How do drug-treatment rates vary across key B-cell NHL / CLL subtypes by line of therapy?
  • What are the key drivers and obstacles determining current prescribing patterns in NHL / CLL?
  • What are the clinical characteristics that physicians consider when prescribing CAR T-cell therapies and bispecific antibodies for the various NHL / CLL subtypes?

Primary research: Survey of 100 hematologist-oncologists in the United States fielded in December 2024

Key drugs covered: Breyanzi, Brukinsa, Calquence, Columvi, Epkinly, Imbruvica, Jaypirca, Kymriah, Lunsumio, rituximab, Tecartus, Venclexta, Yescarta

Product description

Through survey data from U.S. physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:

  • Understand the treatment landscape for a disease and how physicians make prescribing decisions.
  • Evaluate the drivers and obstacles that influence treatment selection.
  • Analyze your brand’s performance from the physician perspective to enhance or defend your competitive position.
  • Create impactful messaging for physicians by identifying brand differentiators and understanding what motivates prescribing behaviors.

Table of contents

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Major Depressive Disorder (DSM-V) – Current Treatment – Current Treatment: Physician Insights – Major Depressive Disorder (EU5)
Across the EU5, the treatment landscape for major depressive disorder (MDD) is shaped by the widespread use of SSRIs and SNRIs, which continue to serve as firstline therapy due to their…
north_east
Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
north_east
Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…
north_east
Report
Eosinophilic Esophagitis – Unmet Need – Unmet Need – Eosinophilic Esophagitis (US/EU)
Standard treatments for eosinophilic esophagitis (EoE) typically include proton pump inhibitors (PPIs) and swallowed topical steroids. Although these therapies can alleviate EoE symptoms, their…
north_east
Report
Breast Cancer – Geographic Focus: China – China In-Depth – Breast Cancer
China’s breast cancer market continues to evolve rapidly, driven by rising incidence and expanding systemic treatment options. Several new and emerging therapies are expected to gain approval for…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east